Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shields

Showing results (331-340 of 413) with videos related to

Pageof 42
Sort By:
Antimicrobial Agents and Chemotherapy|March 6, 2013
Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenemsJae H Hong, Cornelius J Clancy, Shaoji Cheng, et al.
Transplantation|August 2, 2016
Surgical Site Infections After Liver Transplantation: Emergence of Multidrug-Resistant Bacteria and Implications for Prophylaxis and Treatment StrategiesJ Alexander Viehman, Cornelius J Clancy, Lloyd Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 10, 2021
Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant RecipientsM Hong Nguyen, Ryan K Shields, Liang Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 15, 2016
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae InfectionsRyan K Shields, Brian A Potoski, Ghady Haidar, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement TherapyM Biagi, D Butler, X Tan, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2014
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremiaRyan K Shields, M Hong Nguyen, Brian A Potoski, et al.
Journal of Neurotrauma|December 23, 2020
Meeting Proceedings for SCI 2020: Launching a Decade of Disruption in Spinal Cord Injury ResearchLeslie R Morse, Edelle C Field-Fote, Jose Contreras-Vidal, et al.
Physical Therapy|December 21, 2010
The revised research agenda for physical therapyMarc S Goldstein, David A Scalzitti, Rebecca L Craik, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2016
Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort studyKady Phe, Ryan K Shields, Frank P Tverdek, et al.
Antimicrobial Agents and Chemotherapy|March 16, 2016
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa IsolatesDeanna J Buehrle, Ryan K Shields, Liang Chen, et al.
Pageof 42

Showing results (331-340 of 413) with videos related to

Sort By:
Pageof 42
Antimicrobial Agents and Chemotherapy|March 6, 2013
Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenemsJae H Hong, Cornelius J Clancy, Shaoji Cheng, et al.
Transplantation|August 2, 2016
Surgical Site Infections After Liver Transplantation: Emergence of Multidrug-Resistant Bacteria and Implications for Prophylaxis and Treatment StrategiesJ Alexander Viehman, Cornelius J Clancy, Lloyd Clarke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 10, 2021
Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant RecipientsM Hong Nguyen, Ryan K Shields, Liang Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 15, 2016
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae InfectionsRyan K Shields, Brian A Potoski, Ghady Haidar, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2019
Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement TherapyM Biagi, D Butler, X Tan, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2014
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremiaRyan K Shields, M Hong Nguyen, Brian A Potoski, et al.
Journal of Neurotrauma|December 23, 2020
Meeting Proceedings for SCI 2020: Launching a Decade of Disruption in Spinal Cord Injury ResearchLeslie R Morse, Edelle C Field-Fote, Jose Contreras-Vidal, et al.
Physical Therapy|December 21, 2010
The revised research agenda for physical therapyMarc S Goldstein, David A Scalzitti, Rebecca L Craik, et al.
The Journal of Antimicrobial Chemotherapy|August 21, 2016
Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort studyKady Phe, Ryan K Shields, Frank P Tverdek, et al.
Antimicrobial Agents and Chemotherapy|March 16, 2016
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa IsolatesDeanna J Buehrle, Ryan K Shields, Liang Chen, et al.
Pageof 42